Originally Posted by indigogo

From the article:

"This approach, combined with a scientifically-savvy, adequately empowered business development function (Booth's comments here resonate), and intensified engagement with and support of translation-focused disease foundations (a model that I fervently hope will be fruitful and multiply), could result in a promising future for big pharma, a sustainable future for the biomedical innovation ecosystem, and most importantly, a healthier future for patients."


I hate to be a broken record, but we are lucky to have MJFF playing this role for us; no one could be more savvy. It still takes time.